AKT1 and Miyoshi myopathy: Furthermore, we found that anti-CD40 stimulation significantly restored the reduced MM and OCR in BCR-stimulated AKT/2-deficient B cells to levels comparable with those in BCR-stimulated WT Ctrl (CD19Cre) B cells (Fig 8E and F), which could partially account for the rescue of the loss of AKT1/2-deficient GC B cells by in vivo anti-CD40 administration.